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[57] ABSTRACT 
Compositions for treating tissue damage from ischemia 
contain PBN, or active derivatives thereof, which are active 
during ischemia in preventing ATP depletion of the cells 
which predisposes them to subsequent injury during reper 
fusion, and which are active during reperfusion as oxygen 
radical scavengers, in a suitable pharmaceutical carrier for 
systemic or local administration, especially to the CNS, 
spinal column and eyes. Based on animal studies, the dosage 
for treating damage due to stroke is in the range of 10 to 300 
mg/kg. Similar dosages are useful in treating damage result 
ing from free radical generation during in?ammation, either 
as a product of infection or exposure to in?ammatory agents 
or abusive agents, including drugs and alcohol. 
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PHENYL BUTYL NITRONE COMPOSITIONS 
AND METHODS FOR TREATMENT OF 
OXIDATIVE TISSUE DAMAGE 
Matter enclosed in heavy brackets [ ] appears in the 
original patent but forms no part of this reissue speci? 
cation; matter printed in italics indicates the additions 
made by reissue. 
This application is a Reissue ofSer. No. 07/422,651, US. 
Pat. No. 5,025,032. 
BACKGROUND OF THE INVENTION 
This is generally in the area of compositions and methods 
for use thereof for the treatment of oxidative tissue damage 
such as that resulting from ischemia or in?ammation, 
wherein the active compounds are phenyl butylnitrone 
(PBN) or derivatives thereof. 
Oxygenated tissue suffers damage, in many cases perma 
nent damage, if it becomes ischernic and is then reperfused. 
Oxygen free radicals have been implicated in the injury. 
Brain appears to be uniquely susceptible to ischernia/reper 
fusion injury, and neurons are more susceptible than glial 
cells. Certain areas of the brain, for example, the hippoc 
ampus and spinal cord, are more susceptible than other 
regions of the brain. As a result, ischernia/reperfusion injury 
to brain may have a multiplicative effect simply because of 
the necessity for complete integrity of all regions in order to 
have proper functioning. 
Several mechanisms may cause ischernic brain damage. 
For example, the mechanisms responsible for selective neu 
ronal vulnerability may be different from those that cause 
glial swelling and extensive brain edema, and a third set of 
events may underlie such gross functional aberrations as 
seizures. Siesjo, Critical Care Med. 16, 954-963 (1988), has 
grouped the numerous observations into four possible 
mechanisms to explain the injury in brain. These include: 
(A) calcium mediated cell death, (B) excitotoxic damage 
(glutamate buildup), (C) free radical events and (D) acidosis. 
It is likely that all four basic mechanisms are either inter 
related or contribute collectively to the injury observed. 
It now seems likely that selective neuronal vulnerability 
is, at least to some extent, an excitotoxic lesion that is 
triggered by the release of glutamate and/or asparate from 
depolarized nerve endings. At the membrane and molecular 
levels, calcium in?ux via NMDA-activated channels is 
probably crucial, although osmolytic damage to dendritic 
spines and dendrites could contribute. It has never been 
satisfactorily explained, however, how ischernia could cause 
delayed neuronal death. 
The mechanisms that cause laminar necrosis, glial 
distruction, and infarction are more speculative. The inabil 
ity of the cells to regulate their volume may be caused by a 
molecular defect where edema is a conspicuous feature. 
Cells that possess coupled antiporters for Na+lH+ and 
Cl-IHCO3 exchange may regulate pH; at the expense of 
volume regulation, so that edema may be coupled to acido 
sis. 
When ischernia is accompanied by a delayed acidosis 
related damage, it seems likely that the lowering of pH 
causes changes in protein structure and function, which 
“mature” with time and ultimately cause gross membrane 
dysfunction. It is tempting to assume that the primary lesion 
is an iron-catalyzed free-radical damage to membrane com 
ponents, enhanced by the drastic lowering of pHi and/or 
pHe. 
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Free radicals have been postulated to be mediators of 
reperfusion damage. The important production sites of such 
radicals as the superoxide (02-) and hydroxyl (0H) species 
are the mitochondrial respiratory chain and the sequences 
catalyzed by cyclooxygenase and lipoxygenase. However, 
radicals are also formed furing autoxidation of many com 
pounds (e.g., catecholarnines). Several ischernic events 
favor a spurt of free-radical formation, e.g., those causing 
oxidation of polyenoic free fatty acids, release and reuptake 
of catecholarrrines, and oxidation of hypoxanthine by xan 
thine oxidase. Although all these events occur during recir 
culation, when the O2 supply is restored, they represent 
metabolic cascades triggered by agohist-receptor interac 
tions, energy failure, and/or calcium in?ux during the insult. 
Although free radical formation is a likely cause of ischernic 
damage, it has been di?icult to directly demonstrate that 
such formation occurs and/or that it is su?iciently pro 
nounced to overwhelm the antioxidative defense of the 
tissue, Curran, et al., Mol. Cell. Biol. 5, 167-172 (1985). In 
recent years, however, evidence has been obtained that 
ischernia may cause conjugated dienes and malondialdehyde 
to accumulate in the tissue. Nonetheless, it remains to be 
conclusively shown that free-radical damage to unsaturated 
acyl chains in phospholipids, to protein, or to nucleic acids 
constitutes an important part of the ischernic necrosis. At 
present, the evidence is relatively strong for an involvement 
of free-radical mechanisms in vascular injury, but not for 
damage affecting nerve and glial cells. 
Reviews by Hall and Braughler, Free Radical Biol. Med. 
6, 303-313 (1989), Kontos, Physiology of Oxygen Radicals, 
ed. Taylor, Matalon and Ward, pp. 207-216 (Am. Physiol. 
800., Bethesda, Md. 1986), and Ernster, Critical Care Med. 
16, 947-953 (1988), document a signi?cant amount of 
evidence implicating oxidative damage in head and spinal 
cord injury as well as in hemorrhagic stroke and ischernic 
stroke. Most research which strongly implicates the primary 
role of oxidative damage in ischernia/reperfusion injury in 
brain can be grouped into either of two types of studies: 
those which show protection by addition of agents prevent 
ing peroxidative events, or those designed to observe free 
radicals. 
Although no drugs are currently approved for clinical use 
in treating tissue damage due to ischemia, several com 
pounds have been proposed as potentially being effective. 
Mannitol, an osmotic agent and an oxygen scavenger, has 
been added to reperfusion media and may limit damage to 
organs for transplantation. Superoxide dismutase (SOD) has 
been suggested as a means for limiting in vivo oxidative 
damage. The most promising compounds that interfere with 
peroxidation generation are the lazaroids, modi?ed pred 
nisones, described by J. M. McCall, Acta Anesthesia Bel 
gica, First Antwerp Int. Trauma Symp., which have been 
reported to be e?icacious if given during or after ischernia. 
For example, Hall, et al, Stroke 19, 997-1002 (1988), 
demonstrated that the 21-aminosteroid (474006F), which is 
known to prevent peroxidation in brain homogenate, as 
described by Braughler, et al., J. Biol. Chem. 262, 
10438-10440 (1987), protected gerbils against brain dam 
age induced by three hours of unilateral carotid artery 
occlusion. White and Aust and co-workers, Adv. Free Radi 
cal Biol. Med. 1, 1—l7 (1985), and Babbs, Resuscitation 13, 
165—173 (1986), have demonstrated that iron chelators 
protect animals from ischernia/reperfusion injury. 
With regard to direct demonstrations of oxidative events 
during ischernia/reperfusion injury in brain, there are perti 
nent observations using spin-trapping techniques, salicylate 
hydroxylation, protein oxidation, and nucleic acid oxidative 
Re. 35,112 
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damage. Spin-trapping has provided clear evidence impli 
cating free radical production dunng ischemia/reperfusion 
injury. Imaizumi, et al, Neurological Res. 8, 214-220 
(1986), showed that the spin-trap PBN when incubated with 
rat brain homogenate of animals which had experienced 
very low oxygen pressure for 5 min was able to trap an 
apparently lipid-type radical. Kirsch, et al, Pediatric Res. 21, 
202A (1987), stated in a preliminary note that PBN had 
trapped free radicals in post ischemic brains from animals 
pretreated with the spin-trap. McCay’s group have spin 
trapped free radicals in mouse brain, Arch. Biochem. Bio 
phys. 244, 156-160 (1986), and shown that spin-trapped 
free radicals of PBN are present in blood leaving the heart 
of intact dogs recovering from a “stunn " myocardium, J. 
Clin. Invest. 82, 476-485 (1988). As described, the free 
radicals spin-trapped are apparently lipid-type free radicals 
and appear within 1 min after release of occlusion and reach 
peak intensity about 5 min after reperfusion starts. PBN 
enhanced recovery of the post ischernic function of the 
“stunned” heart. 
In summary, while PBN has been used in a number of 
research studies. there has been no data to support the 
proposition that it could be useful in vivo, particularly with 
respect to treatment of tissue damage in the central nervous 
system. In vivo, the drug must be able to (1) cross the blood 
brain barrier and (2) act in a manner which reduces tissue 
damage during or following ischemia. 
It is therefore an object of the present invention to provide 
composition and methods for use thereof which are useful in 
preventing or reversing ischemic damage in vivo,, especially 
in the CNS, spinal cord and eyes. 
It is a further object of the present invention to provide 
compositions and methods for use thereof which are useful 
in preventing or reversing free radical damage in vivo 
resulting from infection and in?ammation. 
It is another object of the present invention to provide 
compositions and methods for use which prevent energy 
depletion of cells during ischemia. 
It is still another object of the present invention to provide 
compositions and methods for use which are useful in the 
treatment of a variety of disorders in addition to those 
resulting from ischemia, including progressive neuronal loss 
from disease or drug and alcohol abuse and disorders 
resulting from photooxidation and exposure to high pressure 
or enriched oxygen. 
SUMMARY OF THE INVENTION 
Compositions for treating tissue damage from ischemia 
contain PBN, or active derivatives thereof, having the fol 
lowing general formula, in a suitable pharmaceutical carrier 
for intravenous administration. 
wherein: 
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X is phenyl or 
(OR)n 
wherein R is H, 
Y 
and n is a whole interger from 1 to 5; or 
Y is a tert-butyl group that can be hydroxylated or acetylated 
on one or more positions; phenyl; or 
OW 
r 
O 0 
II II 
wherein W is C—CH3, NH-—C—Z, 
O 0 
II II 
C-CH3, C-OZ, or Z; and 
Z is a C1 to C5 straight or branched alkyl group. 
Based on animal studies, the dosage for treating damage 
due to stroke is in the range of 10 to 300 mglkg. 
The compositions are administered prior to or during 
ischemia in an effective dosage to prevent or reverse pre 
disposition of the cells to damage resulting from depletion of 
ATP (as demonstrated by in vivo NMR) and damage from 
free radical generation following reperfusion. The preferred 
method of administration is intravenously in humans for 
treatment of stroke. The preferred method of administration 
for treating in?ammation is by directed delivery to the site 
of in?ammation. Examples of diseases which can be treated 
include stroke, meningitis, progressive neuronal loss due to 
Parkinson’s disease, senile dementia, and drug abuse, dis 
orders arising from exposure to high pressure oxygen or 
enriched oxygen environments, and bleeding into nervous 
tissue as a result of trauma. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a graph of the dose-effect curve for the bene?cial 
effects of PBN on transient ischemia-induced hyperactivity, 
plotting locomotor activity versus PBN dose in mgl'kg. 
Young adult gerbils were given a single dose of PBN 1 hr. 
before 5 min of bilateral carotid occlusion. Twenty-four 
hours later the change in spontaneous locomotor activity 
was determined. Control (con) value represent the level of 
exploratory activity of a group of normal naive gerbils. 
Saline (Sal) values were determined in gerbils injected with 
Re. 35,112 
5 
saline 1 hr. prior to ischemia. Data presented represent the 
mean (i'S.E.) for 6 gerbils per treatment group. 
FIG. 2 is a graph of the etfect of PBN on the levels of 
activity in successive 10 min intervals for the test described 
in FIG. 1. Data presented represents the means (iS.E.) for 6 
gerbils per treatment group: control (—0—0-—); 32 mg 
PBN/kg (—A—A—); 100 mg PBN/kg (—[]—-[]—); and 
300 mg PBN/kg (—°—-°—). 
FIG. 3 is a graph of the effects of PBN on the post 
ischemic locomotor activity of aged gerbils (greater than 20 
months of age) tested 24 hrs. after a 2 min period of 
ischemia, as described in FIG. 1. Control (——°—O——); 
saline (——0—0—); and 300 mg PBN/kg (—A—A——). 
FIG. 4 is a graph of the effects of administration of 300 
mg PBN on 15 min. ischemia-induced changes in sponta 
neous locomotor activity of gerbils, plotting locomotor 
activity counts versus time (minutes). Saline treated group 
(—0—0—) represents 5 of the 10 control gerbils 
(—°—°—) tested. The data for PBN (--A—A—) rep 
resents all 10 gerbils tested. Control values are for 6 gerbils. 
All data are expressed as the mean (iSE). Where no SE. is 
indicated, it is within the dimensions of the symbol. 
FIG. 5 is a graph comparing cumulative locomotor activ 
ity counts over successive 10 minute periods for non 
ischemic animals receiving saline (dark [1; 32 mg PBN/kg 
(dark A); 100 mg PBN/kg (.); 300 mg PBN/kg (dark inverted 
A); 500 PBN/kg (dark 0); 1000 mg PBN/kB (0); and 2000 
mg PBN/kg (inverted A). 
FIG. 6 is a bar graph comparing percent survival after a 
lethal occlusion of the carotid arteries in gerbils treated with 
either saline or 300 mg PBN/kg. 
FIG. 7 is a graph comparing the percent carbonyl protein 
of control in gerbils that have been subjected to ischemia, 
ischemia followed by 15 minutes reperfusion, ischemia 
followed by 60 minutes reperfusion, and ischemia followed 
by 60 minutes reperfusion with preischemia administration 
of 300 mg PBN/kg. 
FIG. 8 is a graph comparing percent of glutamine syn 
thase activity of control gerbils that have been subjected to 
ischemia, ischemia followed by 15 minutes reperfusion, 
ischemia followed by 60 minutes reperfusion, and ischemia 
followed by 60 minutes reperfusion with preischemia 
administration of 300 mg PBN/kg. 
FIG. 9 is a graph correlating carbonyl/mg protein versus 
glutmine synthetase speci?c activity, control (—[]--[]—); 
10 minutes ischmia, no reperfusion (—-[inverted AHin 
verted A]—), 10 minutes ischemia, 15 minutes reperfusion 
([ A]~—[ A]—), 10 minutes ischemia, 60 minutes reperfusion 
(—[O]—[O]—), and 10 minutes ischemia, 60 minutes 
reperfusion and PBN (dark [1). 
DETAILED DESCRIPTION OF THE 
INVENTION 
Following ischemia there is a signi?cant increase in free 
radical production (both oxygen and carbon centered radi 
cals). The initial damage to brain cells is thought to result 
from the peroxidation products with subsequent damage 
from secondary (carbon-centered) radicals. Eventually the 
metabolic and synthetic pathways are damaged to such an 
extent that the ceil dies. PBN and functionally equivalent 
spin trapping derivatives that pass through the blood brain 
barrier, prevent cell damage during and subsequent to 
ischemia by decreasing or preventing ATP depletion, and 
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still exhibit spin trapping of oxygen radicals are of bene?t by 
bonding to the carbon-centered-free radicals to prevent 
further damage by the modi?ed enzyme or other constituent. 
As used herein, a free radical scavenger or spin trap reagent 
is a molecule that will form a stable complex with a free 
radical. A free radical carbon trap is a molecule in which the 
free radical is localized on a carbon atom or a nitrogen atom. 
ot-phenyl t-butyl nitrone (PBN), and derivatives thereof, 
in a pharmaceutical vehicle suitable for intravenous admin 
istration are useful in preventing or reversing CNS damage 
following ischemia or in?ammation. As used herein, 
ischemia is de?ned as a blockage of blood ?ow that results 
in a lesion in the central nervous system (CNS), including 
the spinal column and eyes. PBN has a number of advan 
tages in the treatment of ischemia induced damage, includ 
ing being able to pass through the blood brain barrier and 
having no measurable eifect on normal or uninjured cells. 
PBN is the preferred active compound at this time, although 
a number of derivatives are also useful, including hydroxy 
derivatives, especially 2-, 3- or 4~hydroxy PBN and mono-, 
di- and trihydroxy tert-butyl nitrone; esters, especially esters 
which release 2-, 3, or 4-hydroxyphenyl t-butyl nitrone such 
as the acetoxy derivative, 2-, 3-, or 4-carboxyphenyl t-butyl 
nitrone. such as the ethyl derivative, or phenyl hydroxybutyl 
nitrone, such as the acetoxy derivative; alkoxyl derivatives, 
especially alkoxyl derivatives which release 2-, or 4-hydrox 
yphenyl t-butyl nitrone, such as the methyl derivative; and 
acetamide derivatives, especially acetarnide derivatives 
which release 2-, or 4 arninophenyl t-butyi nitrone, such as 
the acetyl derivative; diphenyl nitrone (PPN) and the analo 
gous diphenyl nitrone derivatives. As used herein, “PBN" 
refers to both ot-phenyl t-butyl nitrone and derivatives 
thereof, unless otherwise stated. The active agent in the 
compositions is N-tert-Butyl-a-phenylnitrone (PBN) or 
derivatives thereof that are spin trap reagents and which also 
act to prevent ATP depletion of cells. 
The general formula for PBN and useful derivatives 
thereof is: 
X Y 
wherein: 
X is phenyl or 
(0R)n 
wherein R is H, 
0 0 
Y 
and n is a whole interger from 1 to 5; or 
Re. 35,112 
Y is a tert-butyl group that can be hydroxylated or acetylated 
on one or more positions; phenyl; or 
OW 
a 
h’ l? 
C-CI-Ig, C-OZ, or Z; and 
Z is a C1 to C5 straight or branched alkyl group. 
The compositions can also contain other active agents, 
such as tissue plasrninogen activator, streptokinase, or other 
clot dissolving compounds, other compounds which are 
oxygen radical scavengers such as mannitol or compounds 
which prevent peroxidase generation, such as the lazaroids. 
Examples demonstrate the utility of the compositions in 
preventing brain damage and death in animals following 
blockage of blood ?ow through the carotid artery to the 
brain. Exemplary dosages of PBN ranged from 32 to 300 
mg/kg of body weight in gerbils. The effective range of PBN 
in humans and other mammals is between approximately 10 
and 300 mg/kg. The compositions can be eifectively admin 
istered prior to, during or after ischemia, and prevent or 
decrease the extent of cellular damage. 
The use of compounds which are spin-traps that are 
capable of scavenging oxygen radicals during reperfusion 
following ischemia, and which act to block ATP depletion of 
the cell (which predisposes the cell to injury following 
ischemia), represeats a truly unique approach to the man 
agement of post-ischemic pathologic conditions, and fol 
lowing ischemia associated with surgical procedures (e.g., 
by-pass surgery and transplantation of organs). Since the 
trapping of endogenous free radicals is speci?c for only 
those cells that have been exposed to the conditions that 
result in the production of free radicals, the traps will have 
little or no effect on normal cells. The bene?cial effects will 
occur only in injured cells. Moreover, because the bene?cial 
effect does not require the presence of speci?c receptors or 
speci?c enzymes, the spin traps offer a signi?cant improve 
ment in the treatment of ischemia/induced cellular dysfunc 
tion and necrosis. 
In addition, these compounds should be extremely useful 
for the prophylactic treatment of chronic or periodic cyto 
toxic conditions that involve free radicals. The CNS disease 
conditions that are expected to be treatable using such 
compounds include stroke, transient ischernic attacks, 
Aizheimer necrosis, continued cell loss in Parkinsonism, 
meningitis, cardiac resuscitation-induced brain damage, and 
damage arising as a result of trauma, especially head and 
spinal injuries with associated bleeding from surrounding 
tissues into the nervous tissues. It is expected that these 
compositions can also be used to treat a variety of other 
disorders including damage to the eyes resulting from plac 
ing very premature babies on high oxygen respirators, drug 
and/or alcohol abuse-induced damage to the CNS, as well as 
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other organs, and damage resulting from exposure to ioniz 
ing radiation or photooxidation. 
The PBN is preferably administered systemically, most 
preferably intravenously, or orally, since this is the most 
rapid and e?icient means for directing the active compound 
to the site of free radical generation. However, other meth 
ods of administration can be used, as when PBN is admin 
istered intraperitoneally in the examples, or intranasally 
through the pulmonary tract. The PBN can alternatively be 
administered locally, by intramuscular or subcutaneous 
injection, ointment, or delayed release implant. 
Preferred pharmaceutical careers for intraveaous admin 
istration are saline or phosphate bu?‘ered saline at physi 
ological pH. In the preferred method, PBN is delivered to the 
patient intravenously in a dosage in the range of 10 mg/kg/ 
hr, most preferably in the range of one to three mg/kglhr. The 
dosage can be detetrained for the speci?c disease condition 
and/or species by conducting measurements, as described in 
detail below. In general, an effective dosage is that mount of 
PBN that reduces enzyme activity loss by 25%, decreases 
cell death by 25%, and/or maintains 25% or more of normal 
function. 
The present invention will be further understood with 
reference to the following non-limiting examples demon 
strating methods for determining effectiveness of PBN 
administration for treatment of injury arising from ischemia 
or inflammation and demonstration in animals of the pre 
vention and/or reversal of damage from ischemia. 
Gerbil Stroke Model 
An accepted animal model for determining the e?‘ect of a 
compound on injury arising from a stroke is described by 
Chandler, et al., J. Pharrn. Methods 14, 137-146 (1985). 
Brie?y, Mongolian gerbils are anesthetized with pentobar 
bital (40 mg/kg). A ventral rnidline incision is made in the 
neck. Common carotids are exposed and separated from the 
vagosympathetic nerve trunk. A loop of unwaxed dental 
floss (Johnson and Johnson) is placed around each carotid. 
The ends of the ?oss are each passed through one of the 
lumens of a double lumen catheter (Dural Plastics and 
Engineering, Dural, NSW, Australia). The catheter and den 
tal ?oss are passed through the dorsal musculature and 
exited at the dorsal surface of the neck. The catheter is ?xed 
in position, directly above the carotid artery, using 
cyanoacrylate adhesive at the exit site. The dental ?oss 
length is marked in order to assure that the animal does not 
occlude the carotid during daily cleaning and exploratory 
activity. The ventral incision is closed with 9 mm wound 
clips. After 48 hrs following instrumentation, ischemia is 
produced by gently pulling the looped dental ?oss until the 
artery is occluded. Occlusion of the artery is associated with 
loss of consciousness, ptosis and a change in breathing 
pattern. Previous studies, using direct observation, have 
demonstrated that complete interruption of ?ow occurs 
under these conditions. The occlusion is maintained for 10 
minutes and then the dental ?oss removed to allow complete 
reperfusion. After reperfusion, the catheter is trimmed flush 
with the surface of the neck. 
The animals, male gerbils (50-60 gms), are purchased 
from Tumblebrook Farm, West Brook?eld, Mass, and 
housed in groups of three for at least one week prior to 
instrumentation. Following surgery, the gerbils are singly 
housed in order to avoid the possible accidental induction of 
ischemia by cage mates. Food and water are available ad 
libitum in the home cage. All gerbils are maintained under 
a 12 hr light/dark cycle. 
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EXAMPLE 1 
Determination of the Extent of Peroxidation 
Damage in Brain Tissue 
Measurement of Tissue Damage by Free Radical 
Generation 
Tissue damage can be measured as a function of the 
generation of free radicals. protein carbonyl concentration 
increase, and decrease in glutarnine synthetase enzymatic 
activity. 
Free radicals are found in ischemialreperfusion injured 
gerbil brains. There are several methods effective for mea 
suring the generation of free radicals, including spin trap 
ping and salicylate hydroxylation. Salicylate hydroxylation 
can be used to monitor hydroxyl free radicals in vivo, since 
hydroxylation products (2,5-and 2,3-dihydroxybenzoic 
acids, DHBA) are present in the brains of gerbils pretreated 
with salicylate. The amount of DHBA correlates closely 
with the amount of brain injury observed in this model, as 
shown by Cao, et Neuroscience Lett. 88, 233-238 (1988). 
Oxidative damage to gerbil brain proteins can be assessed by 
protein carbonyl group increase, which occurs as the 
ischemic-lesioned gerbil brain is allowed to reperfuse. Over 
all tissue necrosis is also indicated by a decrease in the 
enzymatic activity of glutamine synthetase (GS) in is 
chemic-lesioned gerbil brain. This decrease increases as 
reperfusion time increases, such that at 60 min the GS 
activity is decreased about 35% from normal values. The 
enzymatic activity of GS is highly sensitive to metal cata 
lyzed oxidative damage. Therefore its loss supports the 
notion that metal catalyzed oxidative damage does occur in 
the reperfusion phase of the ischemic-lesioned gerbil brain. 
GS enzymatically converts glutamate to glutamine and thus 
a decrease in its activity may allow the buildup of glutamate, 
an excitatory toxic amino acid. ' 
Utilizing the ischernia/reperfusion lesioned brain of ger 
bils, it was demonstrated that oxidative damage was occur 
ring, with the evidence as follows: (1) increased levels of 
salicylate hydroxylation products, implicating increased 
hydroxyl free radical flux in lesioned brain, (2) increased 
levels of protein oxidation and a loss of glutamine syn 
thetase activity in lesioned brain, (3) free radical formed 
from spin-traps in lesioned brains, (4) spintrap mediated 
protection from brain ischemia/reperfusion injury, and (5) an 
increased peroxidation capacity of brain during the reper 
fusion phase after an ischernic insult. 
Demonstration of in Vivo Oxygen Free Radical 
Flux by Spin~Trapping and HPIJC with 
Electrochemical Detection 
Spin-trapping and HPLC with electrochemical detection 
(LCED) are used to quantitate hydroxylation products of 
salicylate, formed in part by hydroxyl free radical addition, 
and hydroxyl free radical adducts to DNA and RNA. The 
extreme sensitivity of the LCED methodology, on the order 
of 103 to 104 gain over optical methods, is a distinct 
advantage when attempting to ascertain the ?ux of oxygen 
free radicals in vivo, which may only reach 10-9 M under 
high oxidative stress conditions. It has been demonstrated in 
biochemical systems that OH radicals could be trapped by 
salicylate and quantitated using LCED. 
Electron spin resonance of brain lipid extract is measured 
as follows. Gerbils are administered spin-trap dissolved in 
saline stored cold (protected from light) LP. 1 hr prior to 
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treatment. Gerbils are given an ischemia/reperfusion treat 
ment, or in the case of sham-operated controls, placed in the 
animal holder but not occlusion, for a de?ned period. The 
gerbils are killed by decapitation. The brains are removed 
and placed on a cooled stage within 2 min. The cortex of 
brain is isolated cold and stored at —80° C. for about one 
week until it is extracted. The cortex is homogenized at ice 
temperature in a 0.5% NaCl solution (5 gm/rnl) and the 
homogenate is then extracted with 2:1 chloroform-methanol 
mixture (v/v) to a ?nal dilution of 20-fold the volume of the 
tissue sample. The crude extract is washed thoroughly with 
0.5% NaCl (5:1, v/v) and the mixture is allowed to separate 
into two phases by standing at 4° C. for 2 hr. The organic 
phase is recovered and bubbled with N 2 to obtain a concen 
tration that is needed or the solvent of the organic phase is 
evaporated to dryness and the residue redissolved in chlo 
roform. Finally, the samples are transferred to a Pasteur 
pipette (sealed at the capillary end) and bubbled with N2 for 
5 min. The pipettes are then placed in the sample cavity of 
an IBM Bruker ESP300 EPR spectrometer and scanned for 
the presence of spin adducts. The usual spectrometer settings 
are as follows: Microwave power 19.8 mW; modulation 
amplitude 0.9756, time constant 1310.72 ms; scan range 
100 G;, and scan time 6 min. All spectra are recorded at 
room temperature. The coupling constants can be directly 
obtained from the instrument and since since the instrument 
is controlled by an online computer, simulated spectra of a 
mixture of spin-trapped free radials can be compared with 
the bona?de spectrum obtained in order to make prediction 
regarding the tapped free radicals. An extensive data base of 
spin coupling constants taken in ditferent solvents using 
di?erent systems is used for comparison purposes. 
Spin-traps react with free radicals to form adducts, the 
electron spin resonance (ESR) spectrum, which provides a 
mechanism to deduce the chemical identity of the free 
radicals tapped. The method used for in vivo spin trapping 
was developed by Dr. P. B. McCay in combination with Dr. 
Ed Janzen, as reported by Lai, et al., Arch. Biochem. 
Biophys. 244, 156-160 (1986). Free radicals have been 
spin-trapped in ischemia/reperfusion injury in rat heart by 
Bolli and McCay, J. Clin. Invest. 82, 476-485 (1988). 
The production of free radicals during ischemia/reperfu 
sion induced injury in the gerbil brain was tested using spin 
tapping. Both treated and control animals were administered 
the spin trap PBN (tx-phenyl-t-butyl nitrone) before the 
experimental treatments. The data demonstrate that large 
free radical signals were obtained from the extracts of brains 
of ischemia/repcrfusion treated gerbils in contrast to very 
little signals from sham-operated control animals. Surpris 
ingly, the radicals are not what would be expected when a 
spin-trap reacts with a free radical to produce a spin adduct. 
A six-line spectrum is expected from the spin-adduct of a 
free radical of PBN. The six-line spectrum is due to the free 
electron interacting with the spin l/z nuclear magnetic 
moment of the proton as well as the spin of 1 from the 
nitrogen of the nitroxyl group. In contrast, these spectra are 
only three lines, and are therefore due to the free electron 
interacting with the nitroxyl nitrogen only, which means that 
available protons are displaced at a distance such that thye 
are not in?uencing the free electron. 
The most likely explanation for the results is that PBN 
?rst traps a free radical, possibly a lipid carbon free radical, 
after which the spin-adduct is then oxidized to a nitrone 
which then traps another free radical, yielding a nitroxide 
having properties producing the observed spectra. 
Two other spin-traps, DMPO (5,5-dimethylpyrroline-N 
oxide) and POBN (ot-pyridyl-l-oxide-N-t-butylnitrone), 
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both of which have diiferent chemical structures from PBN, 
yielded nitroxide spectra (very similar, 3-lines, yet with 
slightly different nitrogen coupling constants and different 
intensities) as with PBN in the ischemia/reperfusion treated 
gerbils. It is pertinent to note that if the chloroform/methanol 
extract of brains of animals which have been pretreated with 
PBN is allowed to stand at room temperature for 24 hours, 
then the 3-line signal decays. If, however, more PBN is then 
added to the extracts and it is then incubated for 24 hours 
trapped radial signals are observed in the extract of 
ischemiclreperfusion animals, but signals are not seen in the 
sham-operated controls. Computer simulation of the signals 
developing show that three free radicals are present. One has 
parameters equivalent to the three line nitroxide observed 
previously and the other two are spin-trapped carbon free 
radicals, possibly lipid radicals. These observations indicate 
that oxidative events were started in the ischernic brains but 
not in the sham-operated controls and these events are 
carried over, at least in part, in the lipid extracts. 
Demonstration of lschemia/Repe?’usion Induced 
Increased Peroxidation Capacity of the Brain 
Brain homogenate at ice temperature does not spontane 
ously peroxidase, yet if the temperature is raised to 37° C. 
there is, in contrast to almost all other tissue homogenates, 
spontaneous peroxidation. The rate of peroxidation varies 
with brain region and is highly correlated with the total iron 
content of the brain region. Gerbil brain homogenate per 
oxidizes more rapidly than rat brain. The susceptibility to 
peroxidation of brain homogenate after it has experienced an 
ischemia/reperfusion insult and the effect of time of reper 
fusion was determined. The data were collected from 176 
gerbils. At every time point sham-operated animals were 
used as controls. The data show that after 10 min of ischemia 
there is, if reperfusion is not allowed to occur, a decrease in 
the rate of peroxidation. If reperfusion is allowed to occur 
after ischemia, then the rate of peroxidation increases sig 
ni?cantly over sham-operated control animals in a time 
course fashion. The increase is most rapid in the ?rst 60 min 
then slows, reaching a maximum at 7 days following 
ischemia, after which it decreases to values which were still 
higher than controls at 14 days. 
Brains from gerbils which have been pretreated with 
pentobarbital and then given a 15 min ischemia period 
followed by 15 min reperfusion have no increase in the 
amount of spontaneous peroxidation above sham-operated 
controls. Thus not only does pentobarbital protect gerbils 
from the damage brought about by ischemia/reperfusion 
injury, there is no increased peroxidation of the brain homo 
genate from pentobarbital treated animals as compared with 
untreated animals. Pre-treated animals lesioned by 15 min 
ischemia/l5 min reperfusion had spontaneous brain homo 
genate peroxidation about 15% above sham-operated con 
trols, demonstrating a direct correlation between increased 
brain homogenate peroxidation. 
EXAMPLE 2 
Demonstration of the Protective Effect of 
Spin-Traps in Ischemia/Reperfusion Induced Brain 
Injury in Gerbils 
The spin-trap PBN often considerable protection to the 
gerbil from brain injury brought on by an ischemia/reper 
fusion insult and in addition helps prevent death which often 
accompanies the brain injury. The data demonstrating these 
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statements are presented in FIGS. 1, 2, 3 and Table 1. Table 
I shows that animals given PBN I.P., dissolved in saline, at 
a dosage of 300 mglkg, 60 min prior to 15 min ischemia, 
which is followed by 24 hr reperfusion, protected the 
animals from death, that is, the animals lived for longer than 
7 days, the time point when lethality is evaluated. 0f the 
control animals which received saline, 50% of the yound and 
100% of the old gerbils had died as of the seventh day. 
Gerbils, which have received a brain ischernic insult 
resulting in permanent injury, ?rst exhibit a lethargic reac 
tion then a characteristic increase in spontaneous locomotor 
activity above controls at 4 hours after ischemia. The 
lesion-induced hyperactivity continues for several days. 
Drugs that protect the animals from ischemia/reperfusion 
injury prevent the characteristic rise in spontaneous activity. 
PBN was effective at various dosages in protecting against 
ischemialreperfusion induced hyperactivity, as demon 
strated by Table l and FIG. 1. It can be seen that saline 
treated animals given a 5 min ischemia insult had hyperac 
tivity signi?cantly higher than sham-operated controls 24 hr 
after ischemia. However, animals which had received PBN 
at 32 or 100 mg/kg 1 hr prior to ischemia had no elevated 
hyperactivity. PBN at 300 mg/kg caused a decreased activity 
over controls. Data comparing activity at the 24 hr reperfu 
sion time of sham-operated controls with 2 min ischemia, 5 
min ischemia and 15 min ischemia lesioned animals, which 
had received either saline or 300 mglkg PBN, are shown in 
FIGS. 2, 3 and 4. The data clearly demonstrate that the high 
dose of PBN caused a reduction in ischemia induced hyper 
activity to levels of the control or lower. 
TABLE 1 
I-listopathological Scores in Gerbils 7 days after 5 min 
of Global Cortical Ischemia. 
Group Score 
Control (no ischemia) 4.3 (i5) 
32 mg PBN/kg 2.5 (17) 
100 mg PBN/kg 2.8 (1.4) 
300 mg PBN/kg 1.7 (1.5) 
"N = 6 gerbils per group. 
In order to obtain parameters relative to acute toxicity of 
PBN, total cumulative activity of normal gerbils were inves 
tigated at a wide range of concentrations. The data are shown 
in FIG. 5. Only at PBN concentrations of 1000 mg/kg and 
higher was there any alteration in activity noted. PBN at 
2000 mg/kg was not lethal to animals. The one noted effect 
at high PBN concentrations is an induced lethargic response 
which disappears after 24 hours. 
The e?‘ect of PBN administration on percent survival of 
animals given lethal strokes (15 min ischemia) is shown in 
FIG. 6. 50% of the animals given 15 minutes ischemia died. 
With pre-ischemic treatment with PBN, 100% of the animals 
survived. 
Ischemialreperfusion induced oxidative damage to brain 
proteins. Gerbil brains which had received various treat 
ments were analyzed for carbonyl groups on proteins, a 
measure of oxidative damage to protein, and glutamine 
synthetase activity. The results are shown in FIGS. 7 and 8 
and compared in FIG. 9. 
FIG. 7 shows oxidative damage to protein as measured by 
carbonyl content as a percentage of a control gerbil brain 
given a ten minute ischemia at the indicated time of reper 
fusion. 300 mg PBN/kg was administered one hour prior to 
the onset of ischemia. Carbonyl protein content was elevated 
above control levels in 10 min ischemia treated brains 
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without reperfusion. 
Reperfusion for 15 rnin did not enhance carbonyl protein 
above the ischemia only values. After 60 min reperfusion 
there was a signi?cant increase in carbonyl protein. PBN 
pretreatment prevented this rise. 
FIG. 8 shows the oxidative damage to glutarnine syn 
thetase activity as a percentage of a control gerbil brain 
given a ten minute ischemia at the indicated time of reper 
fusion. 300 mg PBN/kg was administered one hour prior to 
the onset of ischemia. Glutamine synthetase (GS) activity 
was slightly lower than control values after ischemia with no 
reperfusion. With increasing reperfusion time, there was a 
dramatic loss in GS activity such that after 60 min reperfu 
sion, only 65% of the activity remained. PBN pretreatment 
of the animals prevented this loss in GS activity. Since this 
enzyme is considered to be a glial cell marker, this data 
indicates post ischemic damage also occurs in glial cells. 
FIG. 9 shows that there was a good correlation between 
the loss of GS activity versus accumulation of carbonyl 
protein when all of the samples analyzed are compared. 
Ischemia/Reperfusion Induced Gene Expression 
The levels of mRNA for c-fos and c~jun were examined 
in gerbil brain cortex after ischemia/reperfusion. The results 
of 10 min of ischemia followed by 60 min of reperfusion 
demonstrated that both c-fos and c-jun mRNA levels are 
elevated within 60 min after the insult. Control animals and 
animals subjected to the surgery showed lower levels of 
c-fos mRNA was markedly enhanced. Pentobarbital pre 
treatment, which protects the animals from ischemia/reper 
fusion injury, prevented the induced expression of the c-fos 
gene, whereas no pretreatment caused a large increase in 
c-fos mRN A. PBN pretreatment suppresses the level of 
c-fos induction in the ischemia/reperfusion injury. 
01d gerbils are much more sensitive to brain ischemia! 
reperfusion injury than young animals, as shown in Table 2. 
Data are expressed as number surviving/total tested. 
TABLE 2 
Effects of PBN pretreatments on post reperfusion 
lethality in young adult gerbils (3—4 months of age). 
Treatment Age (300 mg PEN/kg) Saline 
control young 15/15 15/ 1 5 
15 min ischemia young 10/10 5110* 
10 min ischemia retired 4/4 0/4 
breeders; (18 me.) 
*All surviving gerbils were subsequently tested for behavioral effects at 24 hr. 
post-ischemia. 
EXAMPLE 3 
E?ectiveness of Spin-Trapping Reagents Other 
Than PBN 
In preliminary studies, the effectiveness of two other 
spintraps, DMPO and POBN, in preventing the acute effects 
of an ischemic insult to brain was tested. The results indicate 
that both DMPO and POBN appear to olfer some protection, 
but DMPO was less effective than POBN which was less 
effective than PBN. 
Modi?cations and variations of the present invention, 
compositions containing PBN and derivatives thereof, and 
methods using the compositions for the treatment of tissue 
damage resulting from ischemia or in?ammation, will be 
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obvious to those skilled in the art from the foregoing detailed 
description. Such modi?cations and variations are intended 
to come within the scope of the following claims. 
We claim: 
1. A method for in vivo treatment of oxidative CNS tissue 
damage [resulting from ischemia or in?ammation] compris 
mg: 
administering oi-phenyl t-butyl nitrone [and derivatives] 
or a derivative thereof [having spin trapping activity 
and preventing ATP depletion in vivo in tissue] having 
the formula: 
11 O 
\ 
C = 
/ 
X Y 
wherein: 
X is phenyl or 
{ORln 
wherein R is H, 
Y 
and n is a whole integer from 1 to 5; or 
Y is a tert-butyl group that can be hydroxylated or 
acetylated on one or more positions; phenyl; or 
OW 
O 0 
II II 
wherein W is C-CHg, NI-I-C-Z, 
0 
II 
0 
II 
c-crn, c-oz. or z; and 
Z is a C1 to C5 straight or branched alkyl group; [and] in 
a pharmaceutically acceptable carrier for delivery of the 
ot-phenyl t-butyl nitrone or derivative thereof to [the 
CNS of] a patient in need of such treatment in a dosage 
effective to prevent or reverse oxidalive CNS tissue 
damage [resulting from ischemia of inflammation] not 
associated with bacterial toxins. 
2. The method of claim 1 wherein the phenyl butyl nitrone 
derivatives are selected from the group consisting of 
hydroxy PBNs, PBN esters, acetoxy PBNs, alkyl PBNs, 
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alkoxyl PBNs, phenyl PBNs. 
3. The method of claim 1 wherein the PBN derivative is 
functionalinzd to release in vivo a compound selected from 
the group consisting of 2-, 3-, and 4-hydroxyphenyl t-butyl 
nitrone; 2-, 3-, and 4-hydroxyphenyl t-butyl nitrone; 2-, 3-, 
and 4-carboxyphenyl t-butyl nitrone; and 2-, 3-, and 4-ami 
nophenyl t-butyl nitrone. 
4. The method of claim 1 comprising as the active 
ingredient u-phenyl t-butyl nitrone. 
5. The method of claim 1 further comprising administer 
ing an agent selected from the group consisting of strep 
tokinase, tissue plasrninogen activator, mannitol, and laz 
aroids. 
6. The method of claim 1 wherein the PBN and deriva 
tives thereof is in a pharmaceutical carrier delivering an 
elfective dosage to a patient to prevent reperfusion injury of 
CNS tissue. 
7. The method of claim 1 wherein the PBN and deriva 
tives thereof is in a pharmaceutical carrier delivering an 
eil‘ective dosage to a patient to prevent CNS tissue damage 
from in?ammation. 
8. The method of claim 1 wherein the PBN and deriva 
tives thereof is provided in a dosage of 10 to 300 mg PBN/kg 
body weight. 
9. The method of claim 1 wherein the composition 
administered during or immediately after a stroke. 
10. The method of claim 1 wherein the composition is 
administered to a patient having a progressive neuronal 
disorder. 
11. The method of claim 1 wherein the composition is 
administered to a patient exposed to high pressure oxygen or 
an oxygen enriched environment. 
12. The method of claim 1 wherein the composition is 
administered to a patient to mitigate damage to cells from 
exposure to a chemical agent. 
13. The method of claim 1 wherein the composition is 
administered to a patient su?‘ering from meningitis. 
14. A composition for in vivo treatment of oxidative CNS 
tissue damage [resulting from ischcmia or in?ammation] not 
associated with bacterial toxins comprising: 
ot-phenyl t-butyl nitrone [and derivatives] or a derivative 
thereof [having spin trapping activity and preventing 
ATP depletion in vivo in tissue] of the formula: 
H O‘ 
\ +/ 
C=N 
/ 
x Y 
X is phenyl or 
(OR)n 
wherein R is H, 
and n is a whole integer from 1 to 5; or 
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Y is a tert-butyl group that can be hydroxylated or 
acetylated on one or more positions; phenyl; or 
OW 
O O 
H ll 
whereinW is C-CHg, NH—C——Z, 
0 
I! ll 
C-CH3, C-OZ, orZ; and 
Z is a C1 to C5 straight or branched alkyl group [further 
comprising a compound selected from the group con 
sisting of streptokinase, tissue plasrninogen activator, 
mannitol and lazaroides] 
a pharmaceutically acceptable carrier for [intravenous] 
administration to a patient, 
wherein the ot-phenyl nitrone is in an amount e?ective to 
prevent tissue damage [resulting from ischemia or 
in?ammation] not associated with bacterial toxins 
wherein the nitrone [and further compound are] is 
present in e?’ective amounts. 
15. The composition of claim 14 wherein the phenyl butyl 
nitrone derivatives are selected from the group consisting of 
hydroxy PBNs, PBN esters, acetoxy PBNs, alkyl PBNs, 
alkoxyl PBNs, phenyl PBNs. 
16. The composition of claim 14 wherein the PBN deriva 
tive is functionalized to release in vivo a compound selected 
from the group consisting of 2-, 3-, and 4~hydroxyphenyl 
t-butyl nitrone; 2-, 3, and 4-hydroxyphenyl t-butyl nitrone; 
2-, 3-, and 4-aminophenyl t-butyl nitrone. 
17. The composition of claim 14 comprising as the active 
ingredient ot-phenyl t~butyl nitrone. 
18. The composition of claim 14 wherein the PBN and 
derivatives thereof is in a pharmaceutical carrier delivering 
an eifective dosage to a patient to prevent reperfusion injury. 
19. The method of claim I wherein the oxidative CNS 
tissue damage is associated with ischemia and wherein the 
route of administering is intravenous. 
20. The method of claim 19 wherein the ischemia is stroke 
and wherein the e?’ective dose is from 10 to 300 mg of 
nitrone compound per kg of body weight. 
21. The method of claim 10 wherein the progressive 
neuronal disorder is due to Parkinson ’s disease. 
22. The method of claim I 0 wherein the progressive 
neuronal disorder is due to senile dementia. 
23. The method of claim I wherein the oxidative CNS 
damage is associated with in?ammation. 
24. The method of claim I wherein the oxidative CNS 
damage is associated with meningitis. 
25. The method of claim I wherein X is 
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(OR)n 
5 
and R is H or Z 
26. The method of claim 25 wherein Y is a ten-butyl 
8'0"!’- 10 
27. A composition comprising: 
nitrone compound of the formula: 
H 0 15 
C: 
X Y 
wherein: 20 
X is phenyl or 
(OR)n 
25 
wherein R is H, 
30 
O O 
I! / 
Z—C—.or Z; or —CH=N , 
\ 
Y 35 
and n is a whole integer from I to 5; or 
0 40 
Y is a tert-butyl group that can be hydroxylated or acetylated 45 
on one or more positions; phenyl; or 
OW 
50 1 
wherein W is 
55 
O 
H II II 
C-CH3, NH-C-Z, 0-02. or Z; 
and 
Z is a C1 to C5 stright or branched alkyl group; 
subject to the proviso that X is not phenyl when Y is 
tert-butyl, in a pharmaceutically-acceptable, orally 
administrable carrier: 
28. The composition of claim 27 wherein Y is tert-butyl, 
X is 
65 
18 
(OR)n 
and R is H. 
29. The composition of claim 2 7 wherein Y is tert-butyl, 
X is 
(OR)n 
andRisZ 
30. A composition comprising: 
nitmne compound of the formula: 
H\ /0 
c=1~1+ 
/ \ 
X Y 
wherein: 
X is phenyl or 
(OR)n 
wherein R is H, 
O 0 
II / 
Z—C—, or Z; or ——CH=N 
\ 
Y 
and n is a whole integer from I to 5; or 
Yis a tert-butyl group that can be hydroxylated or acetylated 
on one or more positions: phenyl; or 
OW 
1 
wherein W is 
0 0 
II II II 
C—-CH3, NH-C-Z. C——0Z, or Z; 
and 
Z is a C1 to Cs straight or branchedI alkyl group; 
Re. 35,112 
19 20 
subject to the proviso that X is not phenyl when Y is 32. The composition of claim 30 wherein Y is tert-butyl, 
tert-butyl in pharmaceutically-acceptable, intrave- X is 
nously-administrable carrier. 
31. The composition of claim 30 wherein Y is tert-butyl, 
X is 5 (011)“ 
g 10 
and R is Z. 
andRisH. * * * =1: * 
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